Abstract:Objective This study evaluated the efficacy and safety of tacrolimus(FK506) as secondary intervention in cyclosporine A(CsA) treated renal transplantation patients with chronic allograft nephropathy(CAN).Methods Sixty-one patients who received a cadeveric renal transplantation in our unit more than 12 months prior to study enrollment and who were being treated with CsA-based immunosuppressive treatment were included,all patients received allograft biopsy and were diagnosed as CAN according to Banff criteria.Patients were differentiated according to following regimen.Patients were either converted to FK506 group(n=31) or remained on their initial CsA-based immunosuppression(CsA group,n=30).An important effectiveness index is the rate of decline of renal function before and after the FK506 conversion,calculated by curve fitting and regression analysis with reciprocal SCr as Y-axis and time as X-axis.Therapeutic effectiveness is defined as improvement or stabilization of renal function.Improvement: slope of serum creatinine less than-5%;Stabilization: slope of serum creatinine between -5% and 5%;Deterioration of renal function: slope of serum creatinine larger than 5%.Results Trough TC,TG and LDL levels remained unchanged in CsA group while statistically reduced in FK506 group.Renal function was markedly improved in FK506 group.Among the twenty-four patients with improvement in the rate of decline of renal function,twenty patients(64.5%) had their regression lines become positive and four patients(12.9%) had their regression lines become less negative.Seven patients(22.6%) had increased rate of decline in renal function with their regression lines becoming more negative.The clinical efficiency after the FK506 conversion for 31 patients was compared with the pathological degree of allograft nephropathy before the conversion,and the lighter the pathological degree was,the higher the improvement rate of renal function was,and vice versa.Graft survival rate was significantly increased in FK506 group(93.5% vs 76.7%,P0.01) follow-up one year.The incidence rates of hypertension,hypertrichosis,gum hypertrophy,liver disfunction,and CMV pneumonia in FK506 group were markedly lower than those in CsA group,63.8% vs 84.6%(P0.01),22.4% vs 53.8%(P0.01),8.6% vs 51.3%(P0.01),6.5% vs 16.7%(P0.01) and 6.5% vs 10.0%(P0.05),respectively.Conclusion FK506 treatment markedly improved abnormality in lipid profile and graft renal function post-transplantation.Conversion from a CsA-based regimen to a tacrolimus-based regimen was an effective alterative for salvage of patients with abnormal graft renal function induced by CAN.

Mycophenolate mofetil and FK506 have different effects on kidney allograft fibrosis in rats that underwent chronic allograft nephropathy

Clinical outcomes in renal allograft recipients switched to long-term immunosuppressive therapy with mycophenolate mofetil after renal transplantation

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

The Prospective Randomized Study on Prevention of Cadaveric Renal Allograft Rejection by Tacrolimus (FK506)

Inhibition of Matrix Metalloproteinases During Chronic Allograft Nephropathy in Rats

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Experience with Mycophenolate Mofetil in the Treatment of Chronic Allograft Nephropathy(a Report of 9 Cases)

Conversion from Cyclosporine to Tacrolimus in Renal Allograft Recipients with Chronic Allograft Nephropathy: A Prospective Single Center Study

Effects of Different Immunosuppresants on CAN by Affecting the TGF-β_1 and Smads Signal Pathway

Electrospun Polymer Fibers Modified with FK506 for the Long-Term Treatment of Acute Cardiac Allograft Rejection in a Heart Transplantation Model.

Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation

The Effect of FK506 on the Early Experimental Membranous Nephropathy Rats

Clinical Study on the Use of FK506 after Renal Transplantation

Therapeutic Effect of Y-27632 on Chronic Allograft Nephropathy in Rats

Protective Effects of Sirolimus by Attenuating Connective Tissue Growth Factor Expression in Human Chronic Allograft Nephropathy.

Comparison of Expression of TGF-β1, its Receptors TGFβ1R-I and TGFβ1R-II in Rat Kidneys During Chronic Nephropathy Induced by Cyclosporine and Tacrolimus

The Effect of FK778 on the Progression of Chronic Allograft Nephropathy in a Rat Model

Conversion from Cyclosporine to Tacrolimus for the Treatment of Chronic Allograft Nephropathy

Rapamycin is Less Fibrogenic Than Cyclosporin A As Demonstrated in a Rat Model of Chronic Allograft Nephropathy

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Clinical Outcomes in the Use of Mycophenolate Mofeil in Liver Transplant Patients with Chronic Renal Dysfunction